ValiRx Share Forecast, Price & News

GBX 20
0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
Today's Range
Now: GBX 20
50-Day Range
MA: GBX 21.12
52-Week Range
Now: GBX 20
Volume190,647 shs
Average Volume926,465 shs
Market Capitalization£13.01 million
P/E RatioN/A
Dividend YieldN/A
ValiRx plc, a biotechnology oncology focused company, engages in developing novel therapeutics and associated biomarkers for cancer in the United Kingdom. The company's lead drug candidates include VAL201, an anti-cancer therapeutic that is in Phase I/II trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth, including endometriosis; VAL301, a reformulation of VAL201, which is in pre-clinical development for the treatment of women with endometriosis; and VAL401, a reformulation of generic drug Risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL101, a candidate produced by GeneICE technology platform to modulate BCl2 expression Â- implicated in cancers. ValiRx plc has collaboration agreement with Oncolytika Limited and Black Cat Bio Limited to develop and evaluate BC201 for patients suffering a hyperimmune response to Coronavirus SARS-CoV2 infection. The company was incorporated in 2000 and is based in Hatfield, the United Kingdom.
ValiRx logo

Industry, Sector and Symbol

Industry Biotechnology
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Cash FlowGBX 0.67 per share
Book ValueGBX 8.10 per share



Market Cap£13.01 million
Next Earnings Date6/28/2021 (Estimated)
OptionableNot Optionable


Are Insiders Buying ValiRx plc (LON:VAL) Stock?
February 23, 2021 |  finance.yahoo.com
ValiRx plc (VAL.L)
August 14, 2020 |  uk.finance.yahoo.com
Valirx Share News (VAL)
June 8, 2020 |  www.lse.co.uk
Valirx Share Price (VAL)
January 15, 2020 |  www.lse.co.uk
See More Headlines


Overall MarketRank

0.67 out of 5 stars

Analyst Opinion: 0.0Community Rank: 1.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
GBX 20
0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VAL News and Ratings via Email

Sign-up to receive the latest news and ratings for VAL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

ValiRx (LON:VAL) Frequently Asked Questions

What stocks does MarketBeat like better than ValiRx?

Wall Street analysts have given ValiRx a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ValiRx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is ValiRx's next earnings date?

ValiRx is scheduled to release its next quarterly earnings announcement on Monday, June 28th 2021.
View our earnings forecast for ValiRx

How were ValiRx's earnings last quarter?

ValiRx plc (LON:VAL) issued its quarterly earnings data on Monday, September, 7th. The company reported ($4.43) EPS for the quarter.
View ValiRx's earnings history

How has ValiRx's stock been impacted by Coronavirus?

ValiRx's stock was trading at GBX 0.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VAL shares have increased by 44,344.4% and is now trading at GBX 20.
View which stocks have been most impacted by COVID-19

Who are ValiRx's key executives?

ValiRx's management team includes the following people:
  • Mr. James Gerry Desler, CFO & Exec. Director (Age 65, Pay $52.89k)
  • Mr. Kevin J. Alexander, Sec. & Independent Non-Exec. Director (Age 65, Pay $25.62k)
  • Dr. Suzanne J. Dilly B.Sc., BSc, Ph.D., CEO & Director (Age 43)
  • Mr. Kumar Nawani, Head of Operations
  • Mr. Tarquin Edwards, Head of Investor Relations & Communications
  • Mr. Mark Treharne, Corp. Devel. Mang.

Who are some of ValiRx's key competitors?

What other stocks do shareholders of ValiRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ValiRx investors own include Petrofac (PFC), boohoo group (BOO), ReNeuron Group (RENE), Falanx Group (FLX), Scirocco Energy Plc (SOLO.L) (SOLO), CyanConnode (CYAN), IQE (IQE), Lloyds Banking Group (LLOY), Eckoh (ECK) and Sareum Holdings plc (SAR.L) (SAR).

What is ValiRx's stock symbol?

ValiRx trades on the London Stock Exchange (LON) under the ticker symbol "VAL."

How do I buy shares of ValiRx?

Shares of VAL and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is ValiRx's stock price today?

One share of VAL stock can currently be purchased for approximately GBX 20.

How much money does ValiRx make?

ValiRx has a market capitalization of £13.01 million.

How many employees does ValiRx have?

ValiRx employs 11 workers across the globe.

What is ValiRx's official website?

The official website for ValiRx is www.valirx.com.

Where are ValiRx's headquarters?

ValiRx is headquartered at 3rd Fl, 16 Upper Woburn Place, LONDON, WC1H 0BS, United Kingdom.

How can I contact ValiRx?

ValiRx's mailing address is 3rd Fl, 16 Upper Woburn Place, LONDON, WC1H 0BS, United Kingdom. The company can be reached via phone at +44-20-30084416.

This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.